Nidlegy (bifikafusp alfa;onfekafusp alfa)
- Region
- 🇪🇺 EU
- Active substance
- bifikafusp alfa;onfekafusp alfa
- Company
- Philogen S.p.A.
- Status
- Application withdrawn
- Therapeutic area
- Melanoma
- Application
- EMEA/H/C/005651
- ATC
- L01XY
- Official record
- www.ema.europa.eu
Indication
Neoadjuvant treatment of adult patients with locally advanced fully resectable melanoma
Regulatory milestones
No milestones recorded in the last year.
Follow Nidlegy
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.